FORM	4
------	---

-
Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)										
1. Name and Address of Reporting Person – POSNER BRIAN M	2. Issuer Name <b>an</b> Cellectar Bioscie			~ .	ol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
C/O CELLECT LE DIOCOUENCEES DIG. 100	3. Date of Earliest Transaction (Month/Day/Year) 01/17/2019						X_Officer (give tille below)         Other (specify below)           Chief Financial Officer			
(Street) FLORHAM, NJ 07932	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State) (Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1.Title of Security 2. Transaction	2A. Deemed	3. Transact					5. Amount of Securities Beneficially		7. Nature	
(Instr. 3) Date (Month/Day/Year)				• • • • • •			Transaction(s)		Beneficial	
	(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	X /	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Numb	er	6. Date Exer	cisable and	7. Title and		8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transact	tion	n of		Expiration Date		Amount of		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Derivativ	ve	(Month/Day/Year)		Underlying		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	)	Securitie	Securities			Securities (Instr. 5)		Beneficially	Derivative	Ownership	
	Derivative					Acquired	d	(		(Instr. 3 and 4)					(Instr. 4)
	Security					(A) or							Direct (D)		
						Disposed	d of					1	or Indirect		
						(D) (Insta 2	4					Transaction(s)			
						(Instr. 3, and 5)	4,						(Instr. 4)	(Instr. 4)	
						and 5)	1								
											Amount				
								Date	Expiration		or North co				
								Exercisable	Date		Number of				
				Code	v	(A)	(D)				Shares				
G. 1				Code	•	(11)	(D)				Shares				
Stock										~					
option	\$ 1.99	01/17/2019		А		30,000		<u>(1)</u>	01/17/2029	Common Stock	30,000	\$ 0	30,000	D	
(right to	<i>Q</i> 1.77	01/1//2019				20,000			01/1//2029	Stock	20,000	ΨŪ	23,000	2	
buy)															

## **Reporting Owners**

Dere estime Oren en Nemer (Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
POSNER BRIAN M C/O CELLECTAR BIOSCIENCES, INC. 100 CAMPUS DRIVE FLORHAM, NJ 07932			Chief Financial Officer				

### **Signatures**

/s/ Christina Blakley, attorney-in-fact for Brian M. Posner	01/18/2019
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This option grant is a contingent grant subject to the following conditions: (i) approval by Cellectar's stockholders of an increase in shares available under the Amended and Restated
   2015 Stock Incentive Plan at the Corporation's 2019 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent
   stockholder approval is received, the grant shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.